Author:
Dubé Marie-Pierre,Lemaçon Audrey,Barhdadi Amina,Lemieux Perreault Louis-Philippe,Oussaïd Essaïd,Asselin Géraldine,Provost Sylvie,Sun Maxine,Sandoval Johanna,Legault Marc-André,Mongrain Ian,Dubois Anick,Valois Diane,Dedelis Emma,Lousky Jennifer,Choi Julie,Goulet Elisabeth,Savard Christiane,Chicoine Lea-Mei,Cossette Mariève,Chabot-Blanchet Malorie,Guertin Marie-Claude,de Denus Simon,Bouabdallaoui Nadia,Marchand Richard,Bassevitch Zohar,Nozza Anna,Gaudet Daniel,L’Allier Philippe L.,Hussin Julie,Boivin Guy,Busseuil David,Tardif Jean-Claude
Abstract
AbstractWe conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10–8) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 × 10–8) in interaction with colchicine (P = 1.19 × 10–5) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.
Funder
Philanthropist donations to the Montreal Heart Institute Foundation
The Government of Quebec
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献